Why Is AdaptHealth Corp. (AHCO) Stock Down -40.72% Today?
Key Takeaways
- AHCO shares plunged approximately 40.72% in Tuesday's trading session following the company's Q2 2026 earnings release.
- The primary catalyst was a massive earnings miss: AdaptHealth reported a loss of $0.99 per share versus analyst expectations of a $0.15 profit, alongside revenue of $740.3 million that fell well short of the $848 million consensus.
- A $144.2 million non-cash goodwill impairment charge drove the company deep into the red, producing a net loss of $145.3 million.
- Full-year guidance was slashed dramatically, with revenue now expected between $2.85 billion and $2.89 billion, down sharply from the prior $3.49 billion midpoint and well below Wall Street estimates.
- Margin compression from a troubled West Coast capitated contract and manufacturer price increases further weighed on profitability and the outlook.
- Traders are now watching for signs of stabilization in the capitated contract performance, the closing of the Diabetes Health divestiture to Cardinal Health, and any further restructuring announcements.
Opening Summary
Shares of AHCO, AdaptHealth Corp.—a leading provider of home medical equipment, supplies, and related services for patients managing chronic conditions such as sleep apnea, respiratory disorders, and diabetes—collapsed approximately 40.72% on Tuesday. The stock last traded around $6.42, down from Monday's close of $10.83. The selloff was triggered by a deeply disappointing second-quarter 2026 earnings report that missed Wall Street expectations by a wide margin and included a sharp reduction in full-year guidance, sending shockwaves through the market.
Earnings Results Deeply Disappoint
AdaptHealth reported Q2 2026 net revenue of $740.3 million, representing 12.7% year-over-year growth but falling significantly short of the consensus estimate near $848 million. While the company highlighted organic revenue growth of 15.9%—its strongest quarterly rate in more than a year—the top-line figure disappointed as the market had anticipated a substantially larger contribution from the company's continuing operations.
The bottom line was where the damage was most severe. AdaptHealth posted an adjusted loss of $0.99 per share, compared with analyst expectations for a profit of $0.15 per share. On a GAAP basis, the net loss attributable to AdaptHealth reached $145.3 million, a stark reversal from net income of $4.2 million in the prior-year period. The primary driver of the loss was a non-cash goodwill impairment charge of $144.2 million, which management attributed to a reassessment of valuations in the Respiratory Health and Wellness at Home reporting units following portfolio changes and evolving market conditions.
Guidance Cut Rattles Investor Confidence
Perhaps even more damaging than the quarterly miss was management's decision to dramatically lower its full-year 2026 outlook for continuing operations. The company now expects net revenue between $2.85 billion and $2.89 billion—down from the prior midpoint of roughly $3.49 billion and well below the analyst consensus. Adjusted EBITDA guidance was reduced to a range of $490 million to $520 million, while free cash flow is now projected at just $80 million to $120 million for the full year.
Management pointed to several headwinds behind the guidance cut: approximately $55 million in costs tied to ramping a large West Coast capitated contract, an estimated $30 million impact from manufacturer price increases effective July 1, and about $15 million in costs related to portfolio rationalization. The sale of the Diabetes Health business to CAH for $235 million in cash—announced concurrently—will also remove roughly $100 million in revenue, including corporate overhead that will remain with AdaptHealth post-divestiture.
Margin Compression and Operational Challenges
Despite delivering robust volume growth across its core Sleep Health and Respiratory Health segments, AdaptHealth's profitability came under severe pressure in the quarter. Adjusted EBITDA declined 3.2% year over year to $132.0 million, while the adjusted EBITDA margin compressed to 17.8% from 20.8% a year earlier. The West Coast capitated contract alone created a $55 million EBITDA headwind, with management acknowledging that roughly two-thirds of that was driven by higher-than-expected patient volumes and the remainder tied to elevated labor and logistics costs.
Free cash flow turned negative, reaching negative $20.9 million in the quarter, as capital expenditures of $166.2 million outstripped operating cash flow of $145.3 million. The company's leverage remains elevated, with total long-term debt of $1.94 billion against unrestricted cash of just $43.3 million and a consolidated leverage ratio of 3.06 times adjusted EBITDA—above management's long-term target range.
Market Context and Trading Activity
The magnitude of the decline placed AHCO among the market's worst performers for the session, with volume surging well above the daily average as investors rushed to reprice the stock. The selloff pushed shares near the lower end of their 52-week range of approximately $6.14 to $13.43. The move was idiosyncratic rather than sector-driven, as broader healthcare indices and the Nasdaq Composite did not exhibit comparable weakness. The company's market capitalization contracted sharply, and the stock now trades more than 51% below its April 2026 peak.
What Comes Next for AHCO
Investors will be closely monitoring the progress of the problematic West Coast capitated contract, which management expects to improve gradually over the next several quarters and reach long-term margin targets by 2027. The closing of the Diabetes Health divestiture to Cardinal Health is expected to provide a cash infusion of $235 million, with proceeds earmarked in part for debt reduction. Key risks include the potential for further margin erosion if cost pressures persist, the execution risk of the company's strategic pivot toward Sleep and Respiratory Health, and the ongoing burden of elevated leverage. With the stock now trading at deeply depressed levels, the next several quarters will be critical in determining whether management can restore profitability and rebuild credibility with the investor community.
Trending AI Robots
For traders seeking systematic, data-driven approaches to navigating volatile markets, Tickeron's Trending AI Robots page offers access to hundreds of AI-powered trading bots covering thousands of tickers. Only the strongest-performing bots under current market conditions are featured in this curated section, with each bot differentiated by strategy, timeframe, performance metrics, and the symbols it trades. Exploring this resource can help investors discover automated trading tools aligned with their specific market outlook and risk tolerance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AHCO's Stochastic Oscillator dives into oversold zone
The Stochastic Oscillator for AHCO moved into oversold territory on August 04, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for AHCO's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The 10-day moving average for AHCO crossed bullishly above the 50-day moving average on July 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AHCO advanced for three days, in of 296 cases, the price rose further within the following month. The odds of a continued upward trend are .
AHCO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 184 cases where AHCO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on July 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AHCO as a result. In of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for AHCO turned negative on August 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at .
AHCO moved below its 50-day moving average on August 04, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for AHCO moved below the 200-day moving average on July 20, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AHCO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AHCO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.606) is normal, around the industry mean (11.291). P/E Ratio (16.491) is within average values for comparable stocks, (66.288). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.078). AHCO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.017). P/S Ratio (0.277) is also within normal values, averaging (36.825).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AHCO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of medical products for both rental and sale
Industry MedicalNursingServices
Advertisement